Nkarta NKTX 深 滬
已收盤 11-14 16:00:00 美东时间
1.87
-0.010
-0.53%
華盛通- 最 高1.93
- 今 開1.88
- 成交量 68.86万股
- 最 低 1.83
- 昨 收 1.88
- 總市值 1.33亿
- 52周最高 3.1553
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 1.31
- 委 比 78.83%
- 總股本 7102.45万
- 歷史最高 79.16
- 量 比 0.98
- 振 幅 5.32%
- 歷史最低 1.28
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Stifel Maintains Buy on Nkarta, Lowers Price Target to $11
Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $12 to $11.
11-12 00:03
Nkarta Q3 EPS $(0.29) Beats $(0.35) Estimate
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 16.43 percent. This is a 25.64 percent increase over losses of $(0.39) per share from the same
11-11 05:47
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
<p>Nkarta reported progress in its NKX019 clinical program for autoimmune diseases, including the initiation of the second dose-escalation cohort and complete B-cell depletion in patients. The company also highlighted its financial position with $316.5 million in cash, projected to fund operations into 2029, and plans to present initial data at a medical conference in 2026.</p>
11-10 21:01
Nkarta to Participate in November Investor Conferences
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in two investor conferences in November 2025. The company will attend the Stifel 2025 Healthcare Conference on November 12 at 10:40 a.m. ET and TD Cowen’s Immunology & Inflammation Summit on November 13 at 5 p.m. ET. A simultaneous webcast will be available on Nkarta’s website, www.nkartatx.com, with a rep...
10-30 17:14
Nkarta To Present NKX019 Data At ACR Convergence 2025 Showing Immune Reset In Non-Hodgkin Lymphoma And Preclinical Efficacy In Vitro Autoimmune Disease Models
Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in
10-22 22:14
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
<p>Nkarta, Inc. announced it will present clinical and preclinical data on its investigational NKX019 therapy at the ACR Convergence 2025 meeting in Chicago. NKX019, an allogeneic CD19-targeting CAR-NK cell therapy, demonstrates robust depletion of pathogenic B cells and potential for treating B-cell driven autoimmune diseases. The poster presentation, titled "NKX019... in hematological malignancy and models of autoimmune disease," will be presen...
10-22 14:07
Nkarta to Participate in a September Investor Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, featuring a fireside chat at 8:30 a.m. ET. The event will be webcast live and available for replay on Nkarta’s website for 90 days. Nkarta develops allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases, utilizing cell expansion, cryopreservation, engineering technologies, and CRISPR-based ge...
09-02 12:01
Nkarta shares are trading higher after the company reported better-than-expected Q2 financial results.
Nkarta shares are trading higher after the company reported better-than-expecte...
08-13 22:44
Needham Reiterates Buy on Nkarta, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $10 price target.
08-13 18:04
